A simple, commercially available blood test to aid in the early detection of lung cancer which:
- Has 7x better PPV and 7x fewer false positives than CT
- Detects all types and all stages of lung cancer, including Stage I and II
- Is reimbursed by Medicare and Private Insurance
- Is non-invasive, with no radiation risk for the patient
Your Challenge with Lung Cancer
How to identify the relatively small percentage of lung cancers (5-50 depending on the level of risk), per 1,000, that are present in your high-risk patient population. Watch clinical overview webcast.
- EarlyCDT-Lung, a simple blood test, measures a panel of autoantibodies that develop in response to tumor associated antigens. View article.
- The presence of autoantibodies to tumor antigens has been reported to be detectable up to 5 years before a tumor becomes definable. View article.
- EarlyCDT-Lung has excellent performance. View article.
- EarlyCDT-Lung, proven in clinical settings. View article
Click image to download a Wall Chart
USE OF EarlyCDT-Lung:
- As a risk assessment test to aid in the early detection of lung cancer in your high-risk patients; most notably long-term smokers and ex-smokers. .
- A new tool to risk stratify pulmonary nodules. See overview.
Recent Journal of the American Medical Association (JAMA) article conclusively proved that "annual screening with chest radiographs over a 4-year period did not significantly reduce lung cancer mortality."
However, per the recent NLST study, early lung cancer detection with CT can reduce mortality rates by 20%. However, issues with CT include high false positive rates, radiation risk & high patient cost.
When used with CT, a positive result can mean 7x cancer risk.